fda bans compounded semaglutide shortage injection products resolved feb 21 2025 is on the list As of February 21, 2025, the updated its drug Did the FDA ban – Flex Certified | FDA Regulated

The bridge from "probiotic evidence in non-GLP-1 populations" to "probiotic use during GLP-1 treatment" rests on biological plausibility and the bidirectional microbiome story described above, not on direct head-to-head trials

In real life, this is the point where a person puts down their fork or spoon and feels that their hunger is satisfied

However, under the Medicare GLP-1 Bridge program announced by CMS in December 2025, eligible Medicare Part D beneficiaries will be able to access Foundayo beginning July 1, 2026, for approximately $50 per month

Best Use: PCOS, metabolic dysfunction, or as an alternative to hormone therapy for weight and insulin management

Brand-name Wegovy retail without coverage, over $22,000